Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04630808 · ClinicalTrials.gov registry record · Phase 3
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Nicox Ophthalmics.
- Completed
- Registry status
- Phase 3
- Development phase
- 696
- Enrollment target
- 20
- Study locations
NCT04630808: Completed Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Nicox Ophthalmics.
NCT04630808 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by Nicox Ophthalmics. The registered enrollment target is 696 participants, above the 265-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (163% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04630808, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by Nicox Ophthalmics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 696 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.
Primary Outcome
Mean IOP change from time-matched baseline at 8AM and 4PM time points at the Week 2, Week 6 and Month 3 Visits in the study eye
Conditions Studied
Interventions
- DRUG NCX 470 0.1%
- DRUG Latanoprost 0.005%
Study Locations (20)
California
- Nicox Clinical Site - Burbank
- Nicox Clinical Site - Garden Grove
- Nicox Clinical Site - Huntington Beach
- Nicox Clinical Site - La Jolla
- Nicox Clinical Site - Murrieta
- Nicox Clinical Site - Newport Beach
- Nicox Clinical Site - Pasadena
- Nicox Clinical Site - Petaluma
- Nicox Clinical Site - Redlands
- Nicox Clinical Site - San Francisco
Florida
- Nicox Clinical Site - Boynton Beach
- Nicox Clinical Site - Delray Beach
- Nicox Clinical Site - Fort Lauderdale
- Nicox Clinical Site - Fort Myers
- Nicox Clinical Site - Jacksonville
- Nicox Clinical Site - Jupiter
Arizona
- Nicox Clinical Site - Chandler
- Nicox Clinical Site - Phoenix
Alabama
- Nicox Clinical Site - Dothan
Connecticut
- Nicox Clinical Site - Danbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 696 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2025-06-25 |
| Phase | Phase 3 |
What the finished NCT04630808 record still lists
NCT04630808 is an interventional study that assigns participants to a tested intervention. The registered 696 participants enrollment target is mid-sized for trials with a published cap, above the 265-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (163% higher).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which NCX 470 0.1% is the first listed.
NCT04630808 names 20 study sites across 5 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04630808 about?
NCT04630808 is a clinical study titled "MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension". The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be admi...
What is the current status of trial NCT04630808?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 696 participants. The study started on 2020-11-09. Estimated completion is 2025-06-25.
What conditions does trial NCT04630808 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT04630808?
The interventions under investigation include: NCX 470 0.1% (DRUG), Latanoprost 0.005% (DRUG).
Who is sponsoring clinical trial NCT04630808?
This trial is sponsored by Nicox Ophthalmics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04630808 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04630808's enrollment target sits among peer trials
696 4th of 54 higher than 51 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05417594 · 695 participants · Phase 1
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- NCT06801834 · 695 participants · Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- NCT03136094 · 698 participants · NA
Suicide in Urban Natives: Detection and Networks to Combat Events
- NCT04928846 · 698 participants · Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI